IDRx
GSK Initiates JPM Deal-making with $1 Billion Acquisition of IDRx for Rare Cancer Treatment
GSK, IDRx, JPM, rare cancer, acquisition, biotech, pharmaceuticals
IDRx Secures $120M for Pivotal KIT Inhibitor Study with Promising Early Data
IDRx, KIT inhibitor, pivotal study, funding, cancer treatment, biotech